Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, Single-arm, Phase 2 study
John Farley, William E. Brady, Vinod Vathipadiekal, Heather A. Lankes, Robert Coleman, Mark A. Morgan, Robert Mannel, S. Diane Yamada, David Mutch, William H. Rodgers, Michael Birrer, David M. Gershenson
Dive into the research topics of 'Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, Single-arm, Phase 2 study'. Together they form a unique fingerprint.